GE Healthcare AS

Newly elected members of Board of Directors consist of internationally merited business and clinical leaders Formation of Scientific and Clinical Advisory Board leverages expertise of renowned Oncoinvent founders to support pipeline advancement OSLO, Norway--(BUSINESS WIRE)-- Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced the appointment of newly elected members of its Board of Directors (BOD) and the formation of a Scientific and Clinical Advisory Board under the leadership of founding scientists Roy Larsen and Øyvind Bruland, previous board members and leading experts in oncology and pharmaceutical development. “We are excited to welcome an internationally renowned group of industry leaders as new members of our Board of Directors. The extensive business and industry experience of these newly elected members will provide valuable guidance and leadership in furthering our mission during this pivotal time in Oncoinvent’s advancement,” said Anders Månsson, Chief Executive Officer of Oncoinvent. “We are also pleased to announce the formation of a Scientific and Clinical Advisory Board, consisting of our highly distinguished founders who are uniquely positioned to support Oncoinvent in our clinical programs. We believe that their breadth of resources and deep scientific knowledge, as well as their continued investment in the company, will provide critical insight as we prepare to move forward with the initiation of a Phase 2b clinical trial for Radspherin® in ovarian cancer, and seek to rapidly advance Radspherin® for colorectal cancer to Phase 3 testing following the completion of our Phase 2a study.” The newly appointed members of the Oncoinvent Board of Directors are as follows: Gillies O’Bryan-Tear, Chair, has over 30 years of experience in the pharmaceutical industry in clinical development, medical management and commercial roles. He has held senior leadership positions at a range of pharmaceutical and biotech companies in the US and Europe including Sanofi Aventis, Bristol-Myers Squibb, GSK, Takeda Pharmaceuticals, and Algeta ASA, and has been involved in multiple product approvals. Dr. O’Bryan-Tear has been an adviser to several US and European biotech companies and has held board positions at Fusion Pharmaceuticals and Clarity Pharmaceuticals. He holds a B.A. and M.B.B.S. from the University of Cambridge and an M.B.A from the Cranfield School of Management. Ingrid Teigland Akay is a founder and managing partner at Hadean Ventures. She also currently serves as a board member for Alex Therapeutics, Neuro Events Labs and Attgeno AB. Dr. Akay has supported start-up companies globally in multiple phases of development, from R&D to commercialization and has had previous medical experience in general medicine, surgery and psychiatry, with exposure to both the public and private sector. She holds a medical degree from Diminished Hochschule Hannover and an M.B.A. in Finance from London Business School. Kari Grønås is a managing director at K&K AS and holds board positions at Arxx Therapeutics, Ultimovacs and Spago Nanomedical AB. She has extensive experience in drug development and commercialization in the pharmaceuticals industry and has been involved in product regulatory approvals, including Xofigo and Hexvix. Ms. Grønås has also held previous leadership and management roles at Algeta ASA, PhotoCure and Nycomed Imaging/Amersham Health (Now GE Healthcare). She holds a M. Pharm. degree from the University of Oslo. Hilde Steineger, Ph.D., is the Chief Operating Officer and co-founder of NorthSea Therapeutics B.V. and Chief Executive Officer at Staten Biotechnology. She has held former board positions at Strongbridge BioPharma, Nordic Nanovector, PCI Biotech, Weifa AS, Inven2, Algeta ASA and Clavis Pharmas ASA. She has extensive experience in strategy and innovation, business development and investor relations, having held leadership positions at BASF and Pronova BioPharma. Dr. Steineger holds a Ph.D. in Medical Biochemistry and an M.Sc. in Biotechnology from the University of Oslo. Orlando Oliveira is Senior Vice President, Head of International at Mirati Therapeutics (acquired by BMS). He has nearly 25 years of experience in the pharmaceutical and biotech industry and has held previous leadership positions at Agios Pharmaceuticals (oncology business acquired by Servier in 2021), TESARO (acquired by GSK in 2019) and Cubist Pharmaceuticals (acquired by Merck/MSD in 2015). He has also held positions in medical, commercial, and general management during his 13 years at Amgen. Mr. Oliveira holds an M.Sc. in Pharmaceutical Sciences and a post-graduate degree in Drug and Pharmacy Law from Universidade de Coimbra. Anne Cecilie Alvik remains as an employee elected board member. In addition, Oncoinvent founding scientists Roy Larsen, Ph.D., and Øyvind Bruland, M.D., Ph.D., previously board members, will lead a newly established Scientific and Clinical Advisory Board. Both Dr. Larsen and Dr. Bruland have extensive experience the development of radiopharmaceuticals, as co-founders of several companies including Oncoinvent AS, Algeta AS, Nordic Nanovector AS, and ARTBIO. About Oncoinvent Oncoinvent AS is a clinical stage company developing innovative radiopharmaceutical technology that delivers precise, alpha-emitting particles across solid cancers. By leveraging internal manufacturing and supply chain capabilities to enable a clinical supply of radioisotopes, the company is advancing a pipeline of novel products that use alpha particles, a higher Linear Energy Transfer (LET) form of radiation, that can potentially eradicate cancer cells. Oncoinvent’s lead candidate, Radspherin®, is designed for treatment of metastatic cancers in body cavities, and its versatility allows it to be deployed for the treatment of a variety of cancer indications. Radspherin® is in two ongoing clinical studies to treat peritoneal carcinomatosis from both ovarian cancer and colorectal cancer. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Oncoinvent’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Oncoinvent’s expectations as of the date of this press release, and Oncoinvent disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. View source version on businesswire.com: Contacts Anders Månsson, Chief Executive Officer mansson@oncoinvent.com Tore Kvam, Chief Financial Officer kvam@oncoinvent.com IR enquiries: Courtney Mogerley, Stern Investor Relations Courtney.Mogerley@sternir.com Source: Oncoinvent AS View this news release online at:

CHICAGO, May 5, 2023 /PRNewswire/ -- The nuclear medicine industry is poised for significant growth in the near future, driven by the increasing incidence of cancer and chronic diseases that require advanced diagnostic and treatment options. Advancements in imaging technology, such as hybrid imaging and PET-CT scans, are also fueling demand for nuclear medicine. Additionally, there is a focus on developing radiopharmaceuticals and theragnostic that can target specific diseases and deliver treatments directly to affected areas. Despite potential challenges such as the high cost of equipment and the shortage of trained professionals, the outlook for the nuclear medicine industry is positive, and it is expected to continue to innovate and improve patient care in the coming years. Nuclear Medicine Market in terms of revenue was estimated to be worth $5.5 billion in 2023 and is poised to reach $9.4 billion by 2028, growing at a CAGR of 11.3% from 2023 to 2028 according to a new report by MarketsandMarkets™. The nuclear medicine market is mainly driven by factors such as rising incidence and prevalence of target disease and need for adoption of nuclear medicine for early diagnosis of diseases. However, hospital budget cuts and high equipment prices have made it difficult for a section of end users to opt for nuclear medicine are challenging the growth of this market. Download an Illustrative overview: Browse in-depth TOC on "Nuclear Medicine Market" 449 - Tables 39 - Figures 359 - Pages Nuclear Medicine Market Scope: The diagnostic nuclear medicine segment is expected to hold the largest market share during the forecast period. On the basis of type, the nuclear medicine market is segmented into diagnostic and therapeutic nuclear medicine. The diagnostic nuclear medicine segment is further categorized as SPECT and PET radiopharmaceuticals, while the therapeutic nuclear medicine segment is further divided into beta emitters, alpha emitters, and brachytherapy isotopes. The diagnostic nuclear medicine segment is expected to holds the largest share of the nuclear medicine market during forecast period. The rising prevalence of cancer and cardiovascular diseases, and advancements in radiotracers are some of the key factors driving the growth of this segment. The diagnostic procedure segment is projected to hold the largest market share during the forecast period. On the basis of procedural volume, the nuclear medicine market is segmented into diagnostic and therapeutic procedures. The diagnostic procedure segment is further categorized as SPECT and PET procedures. The diagnostic procedures accounted for the largest share, in the nuclear medicine market. The large share of this segment can be attributed to the diagnostic radioisotopes finding wider demand and use as compared to therapeutic radioisotopes. The diagnostic application segment is expected to account for the largest share of the nuclear medicine application market in 2022. On the basis of application, the nuclear medicine market is segmented into diagnostic and therapeutic applications. The diagnostic application segment is further categorized as SPECT and PET applications, while the therapeutic nuclear medicine segment is further divided into endocrine tumors, thyroid indications, bone metastasis, lymphoma, other therapeutic applications. The diagnostic application segment is expected to account for the largest share of the nuclear medicine market. The increasing demand for SPECT diagnosis owing to the rising demand for minimally invasive surgeries and targeted radiotherapy is the major factor driving the adoption of the diagnostic application using nuclear medicine. North America accounted for the largest share for players operating in the nuclear medicine market in 2022 On the basis of region, the nuclear medicine market is bifurcated into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America holds the largest share of the nuclear medicine market in 2022. This can be attributed to the rising surge of geriatric population, growing requirement of nuclear medicine in the early diagnosis of diseases, technology advancement for radioisotope production, government funding, and key players in this region are also impelling the nuclear medicine market in the region. Inquiry Before Buying: Nuclear Medicine Market Dynamics: Drivers: Increasing incidence and prevalence of target conditions Development of alpha-radioimmunotherapy-based targeted cancer treatments Initiatives to reduce demand and supply gap of Mo-99 Restraints: Short half-life of radiopharmaceuticals Opportunities: Use of radiopharmaceuticals in neurological applications Growth opportunities in emerging economies Challenges: Hospital budget cuts and high equipment costs Key Market Players: The nuclear medicine market is highly consolidated. Some of the major players operating in this market include GE HealthCare (US), Cardinal Health (US), Curium (France),Bayer AG (Germany), Lantheus Holdings, Inc.(US), Bracco Imaging S.p.A. (Italy), PharmaLogic Holdings Corp. (US), Eczacibasi-Monrol Nuclear Products (Turkey), NTP Radioisotopes SOC Ltd (South Africa), Nordion Inc.(Canada), Advanced Accelerator Applications (France), NorthStar Medical Radioisotopes (US), Eckert & Ziegler (Germany), Isotope JSC (Russia), Siemens Healthineers (Germany), Jubilant DraxImage,Inc. (Canada). Get 10% Free Customization on this Report: Recent Developments: In January 2023, NorthStar Medical Radioisotopes (US) achieved a major milestone in advancing its new technology for non-uranium-based production of the critical medical radioisotope, molybdenum-99 (Mo-99). In November 2022, Curium (France) announced that the US Food and Drug Administration (FDA) approved DaTscan (Ioflupane I 123 Injection) to assist in evaluating adult patients with suspected Parkinsonian Syndromes. In October 2022, Blue Earth Diagnostics (UK) signed a data-sharing agreement with Siemens Healthineers (Germany) and the University Hospital of the Technical University of Munich (TUM) for 18F-rhPSMA-7.3, an investigational PET imaging agent, to support AI-based algorithms development. In January 2021, Advanced Accelerator Applications (France) signed a multi-year exclusive supply agreement for lutetium-177 with the University of Missouri Research Reactor (MURR). Through this agreement, MURR will supply AAA with GMP-quality lutetium-177 chloride, the precursor for developing Lutathera and other Lu-177-based therapeutics. Nuclear Medicine Market Advantages: Accurate diagnosis: nuclear medicine allows for highly accurate diagnosis of various diseases and conditions, including cancer, heart disease, and neurological disorders. This is because it enables imaging and functional assessment at a molecular level, providing more precise information about the disease. Personalized treatment: Radiopharmaceuticals used in nuclear medicine can be customized to target specific tissues or cells, enabling personalized treatment for patients. This approach can improve treatment outcomes and reduce side effects. Minimally invasive: nuclear medicine procedures are minimally invasive and require only small amounts of radioactive materials. This means that they are generally safer and less invasive than surgical procedures. Early detection: nuclear medicine can detect diseases and conditions at an early stage, before symptoms appear. This can lead to earlier treatment and better outcomes. Non-invasive: Nuclear medicine procedures are generally non-invasive, which means they do not require incisions or other invasive techniques. This can lead to faster recovery times and lower risk of complications. Nuclear Medicine Market - Report Highlights: The updated version of the report covers the historical market for the nuclear medicine market for the years 2021 and 2022, the estimated market for 2023, and the forecast for 2028, along with CAGR from 2023 to 2028. UPDATED MARKET OVERVIEW: The current edition of the report covers regulatory bodies, government agencies, and other organizations, industry trends, pricing analysis, key conferences & events, pipeline analysis, and key stakeholders & buying criteria in the market overview chapter. ADDITION OF END USER: The current edition of the report includes the end user chapter. UPDATED COMPETITIVE LANDSCAPE CHAPTER: The competitive landscape chapter has been updated with the company evaluation quadrant (DIVE Matrix), company evaluation quadrant for start-ups, footprint of nuclear medicine/radiopharmaceuticals market by type, and geographical assessment of the top market players. The competitive landscape also includes the updated strategies adopted by key players, a revenue share analysis of the top market players, as well as competitive situations and trends section. COMPANY PROFILES: Company profiles give a glimpse of the key players in the market with respect to business overviews, financials, product offerings, and recent developments. One additional company profile has been added (a total of 25 companies profiled). UPDATED FINANCIAL INFORMATION/PRODUCT PORTFOLIOS OF PLAYERS: The new edition of the report provides updated financial information in the context of the nuclear medicine market until 2022 for each listed company in a graphical representation in a single diagram (instead of multiple tables). This will easily help analyze the present status of profiled companies in terms of their financial strength, key revenue-generating country/region, business segment focus in terms of the highest revenue-generating segment, and investments in R&D activities. UPDATED MARKET DEVELOPMENTS OF PROFILED PLAYERS: Recent developments are important to understand the market trend and growth strategies adopted by players in the global nuclear medicine market space. The current edition of this report provides updated developments of profiled players from January 2019 to March 2023, indicating a continuation of the previous version. Partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions have been the principal growth strategies adopted by the market players in this period. ADDITION OF RECESSION IMPACT: The current edition of the report consists of the impact of the recession on the nuclear medicine/radiopharmaceuticals market. A section on the impact of the recession on all regional markets, such as North America, Asia Pacific, Europe, and Rest of the World have been included. Related Reports: Radiation Detection Monitoring Safety Market - Global Forecasts to 2027 Surgical Robots Market - Global Forecasts to 2027 Electroceuticals Market - Global Forecasts to 2026 Diagnostic Imaging Market - Global Forecasts to 2026 Nuclear Imaging Equipment Market - Global Forecasts to 2025 About MarketsandMarkets™: MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit ™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: Visit Our Website: Content Source: Logo: SOURCE MarketsandMarkets

Kathleen Ulrich, MS, BSN, RN, NEA-BC has joined the leading academic medical center on the West Coast of Florida from Duke University Health System. TAMPA, Fla., May 5, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) has named Kathleen Ulrich, MS, BSN, RN, NEA-BC, to the hospital's leadership team as senior vice president of Surgical Services. Ulrich is an experienced health care professional who brings almost 30 years of nursing expertise to Tampa General. Most recently, she was the assistant vice president of Nursing Perioperative Services at Duke University Health System in Durham, North Carolina. While in this role, Ulrich's responsibilities included clinical, professional and regulatory standards within Perioperative Services, while ensuring services always met the needs of patients, families and team members. She was also responsible for the clinical leadership and management for all functions within Perioperative Services, which includes 106 surgical and procedural rooms. "As an academic medical center, Tampa General provides patients with innovative and advanced surgical procedures every day. Kate brings a wealth of experience to our world-class surgical services team and will ensure that our patients will be at the forefront of new research and breakthroughs in surgery," said Kelly Cullen, executive vice president and chief operating officer, Tampa General. "I've spent almost three decades as a nurse – almost all of that in Perioperative Services – and my new role at Tampa General is a wonderful opportunity to positively impact the continuum of care for patients," Ulrich said. "This role enables me to look at perioperative care holistically across the health system in a way that can truly improve the lives of our patients, and I'm thrilled to work with the outstanding team at Tampa General to provide world-class care to patients." Before Duke University Health System, Ulrich gained clinical expertise and a reputation as a leader in her positions at Greenwich Hospital, part of Yale New Haven Health, Greenwich, Connecticut, and Mount Sinai Medical Center, New York, N.Y. She established her nursing experience as a staff nurse at White Plains Hospital, White Plains, N.Y., and Westchester Square Medical Center, Bronx, N.Y. Her work in Perioperative Services began early in her career and has become the focus of it throughout her time in health care. Nurse Executive Advanced-Board Certified, Ulrich earned her Master of Science in Nursing from Iona College in New Rochelle, N.Y. She is a national speaker of best practices in perioperative services and has participated in speaking engagements at the Association of periOperative Registered Nurses (AORN) Global Surgical and other prominent health care conferences throughout her career. ABOUT TAMPA GENERAL HOSPITAL Tampa General Hospital, a 1,040-bed, not-for-profit, academic medical center, is one of the largest hospitals in America and delivers world-class care as the region's only center for Level l trauma and comprehensive burn care. Tampa General Hospital is the highest-ranked hospital in the market in U.S. News & World Report's 2022-23 Best Hospitals, and is tied as the third highest-ranked hospital in Florida, with seven specialties ranking among the best programs in the United States. Tampa General Hospital has been designated as a model of excellence by the 2022 Fortune/Merative 100 Top Hospitals list. The academic medical center's commitment to growing and developing its team members is recognized by two prestigious Forbes magazine rankings – first nationally in the 2022 America's Best Employers for Women and sixth out of 100 Florida companies in the 2022 America's Best Employers by State. Tampa General is the safety net hospital for the region, caring for everyone regardless of their ability to pay, and in fiscal year 2021, provided a net community benefit worth more than $224.5 million in the form of health care for underinsured patients, community education, and financial support to community health organizations in Tampa Bay. It is one of the nation's busiest adult solid organ transplant centers and is the primary teaching hospital for the USF Health Morsani College of Medicine. With six medical helicopters, Tampa General Hospital transports critically injured or ill patients from 23 surrounding counties to receive the advanced care they need. Tampa General houses a nationally accredited comprehensive stroke center, and its 32-bed Neuroscience, Intensive Care Unit is the largest on the West Coast of Florida. It also is home to the Jennifer Leigh Muma 82-bed neonatal intensive care unit, and a nationally accredited rehabilitation center. Tampa General Hospital's footprint includes 17 Tampa General Medical Group Primary Care offices, TGH Family Care Center Kennedy, TGH Brandon Healthplex, TGH Virtual Health, and 21 TGH Imaging powered by Tower outpatient radiology centers throughout Hillsborough, Pasco, Pinellas and Palm Beach counties. Tampa Bay area residents also receive world-class care from the TGH Urgent Care powered by Fast Track network of clinics. To see a medical care professional live anytime, anywhere on a smartphone, tablet or computer, visit Virtual Health | Tampa General Hospital (tgh.org). As one of the largest hospitals in the country, Tampa General Hospital is the first in Florida to partner with GE Healthcare and open a clinical command center that provides real-time situational awareness to improve and better coordinate patient care at a lower cost. For more information, go to . View original content to download multimedia: SOURCE Tampa General Hospital